Abstract
BO is the leading cause of mortality beyond the first year after transplant in pediatric LTx recipients. Since BO is a histologic diagnosis it often mandates performing an open lung biopsy. BOS is a clinical diagnosis based on spirometric data that is the accepted standard for staging chronic allograft dysfunction. The use of predicted values for pediatric recipients has not been validated. We determined the sensitivity, specificity, positive and negative predictive values (PPV and NPV) of the BOS stages for predicting BO in children.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
